Does Trelegy (fluticasone furoate, vilanterol, umeclidinium) contain a Long-Acting Muscarinic Antagonist (LAMA) component?

Trelegy Contains a LAMA Component

Yes, Trelegy (fluticasone furoate, vilanterol, umeclidinium) contains umeclidinium bromide, which is a Long-Acting Muscarinic Antagonist (LAMA). 1

Components of Trelegy

Trelegy is a triple therapy inhaler that contains three active ingredients:

1. Fluticasone furoate - an inhaled corticosteroid (ICS)
2. Vilanterol trifenatate - a long-acting beta2 agonist (LABA)
3. Umeclidinium bromide - a long-acting muscarinic antagonist (LAMA) 1, 2

Role of the LAMA Component in Trelegy

The LAMA component (umeclidinium) in Trelegy provides several important benefits:

• LAMAs improve symptoms and lung function in COPD patients 3
• LAMAs reduce exacerbations and related hospitalizations 3
• LAMAs have been shown to have a greater effect on exacerbation reduction compared to LABAs 3
• Umeclidinium specifically acts as a muscarinic receptor antagonist to produce bronchodilation 4

Clinical Significance of Triple Therapy

The combination of LAMA/LABA/ICS in Trelegy offers advantages for patients with moderate to severe COPD who are not adequately controlled on dual therapy:

• Triple therapy with LAMA/LABA/ICS is recommended for patients with persistent symptoms and exacerbations despite dual therapy 3
• The combination of all three medication classes (LAMA, LABA, and ICS) in a single inhaler may improve patient adherence 5
• For patients with severe COPD (Group D according to GOLD classification), triple therapy is often needed to control symptoms and prevent exacerbations 3

Important Considerations

When using Trelegy, healthcare providers should be aware of:

• The increased risk of pneumonia associated with the ICS component (fluticasone) 3, 5
• Potential side effects of the LAMA component including dry mouth, urinary retention, and worsening of narrow-angle glaucoma 5
• The need for regular assessment of symptom control and exacerbation frequency 5

The LAMA component (umeclidinium) is a key part of this triple therapy combination, providing additional bronchodilation beyond what can be achieved with LABA/ICS alone 6.